Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Plasmodium falciparum infection induces T cell tolerance that is associated with decreased disease severity upon re-infection.

Muñoz Sandoval D. et al, (2025), J Exp Med, 222

An experimental model of clinical immunity for human malaria

Hou MM. et al, (2025)

Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled phase 2b trial in children

Natama HM. et al, (2024)

Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5.

Wang LT. et al, (2024), Cell, 187, 4981 - 4995.e14

Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.

Mertens JE. et al, (2024), Vaccine, 42, 3621 - 3629

First Phase 1b, single-center, age de-escalation trial of theP. falciparumblood-stage malaria vaccine candidate RH5.1/Matrix-M™: a delayed boost regimen induces high levels of functional antibodies in 5-17 month old Tanzanian infants

Silk SE. et al, (2024)

Include forthcoming?